<?xml version="1.0" encoding="UTF-8"?>
<p id="p0115">National Infectious Diseases Clinical Medical Research Center and the Shenzhen Third People's Hospital obtained remarkable results on February 14, 2020, from a clinical study on favipiravir for the management of COVID-19 (
 <xref rid="bib102" ref-type="bibr">News: szdsyy, 2020</xref>). Preliminary findings from a total of eighty patients suggested that the antiviral activity of favipiravir was more efficient than that of lopinavir/ritonavir. No potential side effects in the favipiravir treated groups were found, and it had substantially less detrimental effects than the lopinavir/ritonavir group (
 <xref rid="bib16" ref-type="bibr">Chen et al., 2020a</xref>). In a study involving 240 COVID-19 patients, favipiravir was considered as preferred treatment compared to arbidol (
 <xref rid="bib16" ref-type="bibr">Chen et al., 2020a</xref>).
</p>
